Effect of Continuous Positive Airway Pressure on Lipid Profiles in Obstructive Sleep Apnea: A Meta-Analysis

Baixin Chen 1,2, Miaolan Guo 3, Yüksel Peker 4,5,6,7, Neus Salord 8, Luciano F. Drager 9,10, Geraldo Lorenzi-Filho 11,12, Xiangdong Tang 12 and Yun Li 1,2,*

1 Department of Sleep Medicine, Shantou University Mental Health Center, Shantou University Medical College, Shantou 515065, China; 15bxchen@stu.edu.cn
2 Sleep Medicine Center, Shantou University Medical College, Shantou 515041, China
3 Department of Nursing, Shantou University Medical College, Shantou 515041, China; mlguo@stu.edu.cn
4 Department of Pulmonary Medicine, School of Medicine, Koç University, 34010 Istanbul, Turkey; yuksel.peker@lungall.gu.se
5 Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden
6 Department of Clinical Sciences, Respiratory Medicine and Allergology, Faculty of Medicine, Lund University, 22185 Lund, Sweden
7 Division of Pulmonary, Allergy, and Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
8 Multidisciplinary Sleep Unit, Department of Respiratory Medicine, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Hospital de Llobregat, 08907 Barcelona, Spain; nsalord@bellvitgehospital.cat
9 Unidade de Hipertensao, Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo 05403-904, Brazil; luciano.drager@incor.usp.br
10 Unidade de Hipertensao, Disciplina de Nefrologia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo 05403-900, Brazil
11 Laboratorio de Sono, Divisao de Pneumologia, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo 05508-220, Brazil; geraldo.lorenzi@gmail.com
12 Sleep Medicine Center, Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu 610041, China; tangxiangdong@scu.edu.cn
* Correspondence: s_liyun@stu.edu.cn; Tel./Fax: +86-(754)-8290-2709

Abstract: Background: Obstructive sleep apnea (OSA) is associated with dyslipidemia. However, the effects of continuous positive airway pressure (CPAP) treatment on lipid profiles are unclear. Methods: PubMed/Medline, Embase and Cochrane were searched up to July 2021. Randomized controlled trials (RCTs) of CPAP versus controls with ≥4 weeks treatment and reported pre- and post-intervention lipid profiles were included. Weighted mean difference (WMD) was used to assess the effect size. Meta-regression was used to explore the potential moderators of post-CPAP treatment changes in lipid profiles. Results: A total of 14 RCTs with 1792 subjects were included. CPAP treatment was associated with a significant decrease in total cholesterol compared to controls (WMD = −0.098 mmol/L, 95% CI = −0.169 to −0.027, p = 0.007, I² = 0.0%). No significant changes in triglyceride, high-density lipoprotein nor low-density lipoprotein were observed after CPAP treatment (all p > 0.2). Furthermore, meta-regression models showed that age, gender, body mass index, daytime sleepiness, OSA severity, follow-up study duration, CPAP compliance nor patients with cardiometabolic disease did not moderate the effects of CPAP treatment on lipid profiles (all p > 0.05). Conclusions: CPAP treatment decreases total cholesterol at a small magnitude but has no effect on other markers of dyslipidemia in OSA patients. Future studies of CPAP therapy should target combined treatment strategies with lifestyle modifications and/or anti-hyperlipidemic medications in the primary as well as secondary cardiovascular prevention models.

Keywords: obstructive sleep apnea; continuous positive airway pressure; lipid profile; total cholesterol
1. Introduction

Obstructive sleep apnea (OSA) is one of the most common sleep disorders in adults, affecting nearly 1 billion individuals worldwide [1]. Obesity [2] and dyslipidemia [3] frequently co-exist among patients with OSA. Findings from large cross-sectional studies show increased prevalence of dyslipidemia among OSA patients in a dose-response manner [3]. Several pathological mechanisms including chronic intermittent hypoxia (CIH) [4–7], sympathetic overactivation [8,9] and sleep fragmentation [10,11] may cause lipid profile dysregulation in OSA. For example, consistent evidence from animal models of OSA has shown that CIH induces fasting dyslipidemia due to activation of the transcription factor sterol regulatory element-binding protein 1 (a master transcription factor that controls lipid metabolism) and overexpression of stearoyl-CoA desaturase-1 (an important downstream enzyme of triglyceride and phospholipid biosynthesis) [12]. Moreover, CIH also impaired clearance of triglyceride-rich lipoproteins, inactivating adipose lipoprotein lipase [13,14].

In theory, continuous positive airway pressure (CPAP), the first-line treatment for OSA, eliminates CIH and therefore is expected to improve dyslipidemia. However, findings of previous studies regarding CPAP effects on each lipid profile have been inconsistent. A meta-analysis including 6 randomized controlled trials (RCTs) with 741 participants showed that CPAP treatment decreased total cholesterol (TC) for 0.15 mmol/L, but no changes in levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL) nor triglyceride (TG) [15] were observed. Another meta-analysis including 6 RCTs with 699 participants showed that CPAP treatment decreased the levels of TC for 0.16 mmol/L, HDL for 0.03 mmol/L and TG for 0.32 mmol/L respectively [16]. However, this meta-analysis included an RCT [17], which was retracted later. Furthermore, these two meta-analyses included crossover studies [17–20], and both included data from post crossover periods, which is not recommended by the Cochrane Handbook [21], given that this may induce a carry-over effect. Moreover, most RCTs included in these two meta-analyses have relatively short follow-up durations, i.e., over 80% included RCTs with follow-up durations shorter than 24 weeks. Another meta-analysis including 29 cohort studies with 1958 participants showed that CPAP treatment decreased TC and LDL and increased HDL [22]. In addition, findings from the three aforementioned meta-analyses may be influenced by potential publication bias since their article searches were performed using the specific keywords “lipid profile” and might omit some eligible studies with negative findings of CPAP effects on lipid levels. For example, the study by Nguyen et al. in 2010 [23] analyzed lipid profiles as a secondary outcome, but no significant lipid-lowering effect of CPAP was observed. Taken together, the effect of CPAP treatment on lipid profiles in OSA is yet not well understood.

After publication of the three aforementioned meta-analyses, new RCTs with longer follow-up durations have been published. Because both OSA and dyslipidemia are highly associated with cardiometabolic disease [24–26], here is a need for an update to address the effect of CPAP on lipid profiles in OSA, which was the rationale for the current study.

2. Methods

Search Strategy and Selection Criteria

This meta-analysis was registered in the Prospective Register of Systematic Reviews (CRD 42020201177) and conducted according to Preferred Reporting Items for Systematic Review and Meta-analysis Protocols [27]. We searched PubMed/Medline, Embase and Cochrane Central Register using the following key terms: “obstructive sleep apnea” AND “continuous positive airway pressure” AND “randomized controlled trial”. The literature search was up to July 2021 with no language restrictions. Table S1 presents the specific search strategies for each database, Figure 1 shows the study selection process and Table S2 lists the included studies.
The review of search results was conducted independently by two researchers (Guo M. and Chen B.). Any inconsistency was adjudicated by the senior author (Li Y.). Studies were eligible if they were: (1) studies recruiting adults with OSA (age ≥ 18 years), (2) RCTs with CPAP and control groups (either sham-CPAP or usual care treatment) with at least 4-week follow-up duration, (3) trials reporting mean and standard deviation (SD)/standard error of any of the 4 plasma lipid profiles (e.g., TC, TG, HDL or LDL) during pre- and post-intervention periods and (4) of any language; there was no restriction. Submitted data from one of the RCTs [28] were provided by the principal investigator of the main study [29]. We excluded studies if they: (1) were designed to examine the effects of anti-hyperlipidemic medications on lipid profiles, (2) involved active weight loss interventions (i.e., vertical banded gastroplasty), (3) included pregnant women, (4) were non-randomized designs or crossover trials or (5) were reviews, editorials, letters or case reports.

3. Data Analysis

Two researchers (Guo M. and Chen B.) independently extracted key characteristics (e.g., first author’s name, publication year, sample size, inclusion criteria, percentage of males, percentage of patients on anti-hyperlipidemic medications, et al., Table 1) and target outcomes (e.g., baseline, endpoint and delta values (endpoint minus baseline values) of TC, TG, HDL or LDL) of each trial. Cardiometabolic disease was defined as resistant hypertension, coronary artery disease or diabetes. The Cochrane Collaboration Tool was used to assess quality and risk of bias of included RCTs [30] (Table S3). In this study, we converted all lipid profiles data from mg/dL to mmol/L for meta-analysis (Supplementary Text).
Table 1. Characteristics of the 14 included studies.

| Study (First Author, Year) | N, CPAP | N, Control | Inclusion Criteria | Cardiometabolic Disease | Country | Sham-CPAP Controlled | Age (Year) | Male (%) | BMI (kg/m²) | Follow-Up (Week) | Baseline ESS | AHI (Event/Hour) | CPAP Compliance (Hour/night) | Use of Anti-hyperlipidemic Medications (%) |
|----------------------------|---------|------------|-------------------|-------------------------|---------|---------------------|------------|---------|-------------|----------------|-------------|----------------|---------------------------------|----------------------------------------|
| Robinson, 2004             | 108     | 112        | ESS > 9; ODI > 10; Male | No                     | UK      | Yes                 | 45.5       | 100    | 29.9        | 4              | 16.2        | 38.7           | 5                               | -                                      |
| Drager, 2007               | 12      | 12         | AHI > 30; BMI ≤ 35; Age < 60; Non-HT; Non-diabetes; Male | No               | Brazil  | No                  | 53.4       | 100    | 29.8        | 16             | 13.5        | 59             | 6                               | -                                      |
| Nguyen, 2010               | 10      | 10         | AHI ≥ 15; ESS > 10 | No               | USA     | Yes                | 57.7       | 90     | 32.4        | 12             | -           | 35.2           | 5.1                             | -                                      |
| Craig, 2012                | 172     | 174        | ODI > 7.5       | No               | UK, Canada | No       | 56       | 78      | 32          | 24             | 8           | 13.4           | 2.65                            | -                                      |
| Pedroza, 2013              | 19      | 16         | AHI ≥ 15; RHT | Yes              | Brazil   | No                  | 69.9       | 77     | 33.8        | 24             | 10          | 29             | 6.01                            | -                                      |
| McMillan, 2015             | 114     | 117        | Age ≥ 65; ODI > 7.5; ESS ≥ 9 | No               | UK       | No                  | 53.7       | 81.7   | 30.2        | 48             | 11.6        | 28.7           | 1.9                             | -                                      |
| Feres, 2015                | 22      | 23         | AHI > 5; BMI ≤ 40 | No               | Brazil   | Yes                | 46.6       | -      | 47.4        | 24             | -           | 40.2           | -                               | -                                      |
| Salord, 2016               | 42      | 38         | AHI > 30; Non-diabetes; BMI ≥ 35 with obesity co-morbidity or BMI ≥ 40 | No               | Spain    | No                  | 62.1       | 27.5   | 23.0        | 12             | 7.9         | 60.8           | 5.4                             | 6.3                                    |
| Huang, 2016                | 37      | 33         | AHI ≥ 15; Newly diagnosed coronary artery disease; Non-diabetes; BMI < 25; ESS < 14 | Yes              | China     | No                 | 54.5       | 83.3   | 30.8        | 48             | 9           | 28.9           | 100                            | 4.2                                    |
| Lam, 2017                  | 32      | 32         | AHI ≥ 15; Diabetes | Yes             | Hongkong | No                 | 57.1       | 81     | 33.7        | 12             | 7.5         | 45.3           | 2.5                             | -                                      |
| Rodriguez, 2017            | 151     | 156        | AHI ≥ 15; Female | No               | Spain     | No                  | 54.8       | 0      | 33          | 12             | 9.8         | 32             | 4.8                             | 34.5                                   |
| Pascual, 2018              | 30      | 27         | AHI > 20; Erectile dysfunction | No               | Spain     | No                  | 49.4       | 100    | 35.8        | 12             | 10.2        | 51.6           | 5.3                             | 25.3                                   |
| Silva, 2020                | 31      | 23         | AHI: 5–15; Age < 65; BMI < 35 | No               | Brazil    | No                  | 47.4       | 51.9   | 28.4        | 48             | -           | 9.7            | 3.8                             | -                                      |
| Celik, 2022                | 94      | 102        | AHI ≥ 15; ESS < 10; Coronary artery disease | Yes              | Sweden   | No                  | 66         | 84.2   | 28.3        | 38             | 5.5         | 28.8           | 3.3                             | 95                                     |

AHI = apnea–hypopnea index; BMI = body mass index; CPAP = continuous positive airway pressure; DBP = diastolic blood pressure; ESS = Epworth Sleepiness Scale; HT = hypertension; ODI = oxygen desaturation index; SBP = systolic blood pressure; RCT = randomized controlled trial; RHT = resistant hypertension. -indicates that the value was not reported.
4. Statistical Analysis

The mean value and SD of change in TC, TG, HDL or LDL for each group were calculated according to the Cochrane Handbook [30]. The weighted mean difference (WMD) was used to assess the effect size. The heterogeneity was assessed by \( I^2 \). Random or fixed effects model was conducted in the presence (\( I^2 > 50\% \)) or absence (\( I^2 \leq 50\% \)) of heterogeneity, respectively [30]. To explore the potential moderators of change in lipid profiles after CPAP treatment, meta-regression models were performed by using TC, TG, HDL and LDL as the outcomes and using age, male percentage, body mass index (BMI), obesity (the studies in which mean BMI \( \geq 30 \text{ kg/m}^2 \)), Epworth Sleepiness Scale (ESS), apnea–hypopnea index (AHI), follow-up duration, CPAP compliance and studies that recruited only patients with cardiometabolic diseases patients as independent variables, respectively, according to possible clinical relevance. Due to the limited numbers of included studies, only one independent variable was meta-regressed at each time.

Publication bias was assessed by the inspection of funnel plot [31]. The trim and fill method was used to assess the influence of potential publication bias in case of absence of heterogeneity (\( I^2 \leq 50\% \)) [21]. Sensitivity analyses were used to test the stability of results. A level of \( p \)-value <0.05 was considered statistically significant. All statistical analyses were conducted by using Stata (STATA 14.0, Stata Corp, College Station, TX, USA) and R Project (R 3.4.2, R Foundation for Statistical Computing, Vienna, Austria).

5. Results

A total of 14 RCTs with 899 patients in the CPAP group and 893 patients in the control group were included. The main characteristics of included studies are presented in Table 1. Among the 1792 subjects included, the mean age was 55.3 \( \pm \) 7.1 years, baseline BMI was 32.0 \( \pm \) 5.4 kg/m\(^2\) and 78.2\% were males. The median follow-up duration of included study was 20 weeks (range: 4 to 48 weeks), and median CPAP compliance was 4.8 hours/night (range: 1.9 to 6.0 hours/night).

A total of 11 studies with 1638 patients provided available data of TC levels at pre- and post-CPAP treatment periods. Fixed-effects meta-analysis showed that CPAP treatment resulted in a significant decrease in TC levels (WMD = \(-0.098\) mmol/L, 95\% CI = \(-0.169\) to \(-0.027\), \( p = 0.007, I^2 = 0.0\% \), Figure 2). No significant publication bias was observed by the inspection of funnel plot (Figure S1). After trim and fill methods, results were similar (Figure S2 and Table S4). Sensitivity analysis confirmed the stability of result that it was not violated after omitting any particular study (Table S5). Moreover, meta-analyses showed no significant differences in changes in TG (14 studies, 1792 patients, WMD = \(0.074\) mmol/L, 95\% CI = \(-0.056\) to 0.205, \( p = 0.264, I^2 = 75.4\% \)), HDL (13 studies, 1572 patients, WMD = \(-0.032\) mmol/L, 95\% CI = \(-0.108\) to 0.044, \( p = 0.408, I^2 = 92.3\% \)) and LDL (12 studies, 1492 patients, WMD = \(-0.064\) mmol/L, 95\% CI = \(-0.185\) to 0.056, \( p = 0.296, I^2 = 86.0\% \), Figure 2) between the CPAP group and control group. No significant publication bias of TG, HDL and LDL was observed by the inspection of funnel plot (Figure S1). Sensitivity analyses confirmed the stability of results for TG, HDL and LDL and that they were not violated after omitting any particular study (Table S5).

Meta-regression models were conducted to determine the potential moderators of CPAP treatment effect on the changes in lipid profiles. However, no significant association was found between each lipid profile and age, gender, BMI, obesity, ESS, AHI, follow-up duration, CPAP compliance and studies that recruited only patients with cardiometabolic diseases patients (all \( p \)-value > 0.05, Table S6). Furthermore, in the sub-group analyses of follow-up duration with 12, 16 and 20 weeks as cut-off points, respectively, no significant between-group difference of any lipid profile was observed (all \( p \)-value > 0.05). Moreover, sub-group analyses by different diagnostic criteria for OSA (using AHI versus using oxygen desaturation index) showed no significant differences between the two groups in each lipid profile (all \( p \)-value > 0.1).
Figure 2. Forest plots for changes in lipid profiles after CPAP treatment. CPAP = continuous positive airway pressure, HDL = high-density lipoprotein, LDL = low-density lipoprotein, TC = total cholesterol, TG = triglyceride, WMD = weighted mean difference. Panel (A) Change in TC. Panel (B) Change in HDL. Panel (C) Change in LDL. Panel (D) Change in TG.

6. Discussion
This is an updated meta-analysis including 14 RCTs with a total of 1792 participants (as many as twice the number of RCTs and participants compared to the previous ones). Our findings indicate that CPAP treatment decreases TC in adults with OSA, though only by a relatively small magnitude. However, there is no effect of CPAP treatment on TG, HDL and LDL levels in adults with OSA.

In 2014, two meta-analyses including RCTs examined the effect of CPAP treatment on lipid profiles in OSA and found that CPAP treatment promoted decreased TC for 0.15 and 0.16 mmol/L, respectively [15,16]. In the current study, we have a similar finding of decreased TC after CPAP treatment, but this effect was of a smaller magnitude. The lower rate of decrease of TC in the current study may be partially interpreted by the fact that we used a less restricted search strategy and included more studies reporting negative findings of CPAP effects on changes in lipid profiles. As for other lipid profiles (i.e., TG, HDL and LDL), no changes after CPAP treatment were observed, which is consistent with the previous meta-analyses [15,16,22], suggesting CPAP therapy promotes limited improvement of dyslipidemia in OSA.

The underlying mechanisms for reduction of TC levels after CPAP treatment in OSA are unclear. First, it could be associated with the improvement of CIH by CPAP. CIH, one of the main pathological conditions in OSA, upregulates the pathways of hepatic liver biosynthesis in a fasting state [4] and delays post-prandial lipid clearance [5,13,14] through inducing activation of the enzyme of triglyceride and phospholipid biosynthesis [12], excessive production of reactive oxygen species [6] and low-grade inflammation [7], which has been proposed as one of the main mechanisms for OA-inducing hyperlipidemia. Since
TC is one of the first components to respond to the reduction in oxidative stress associated with OSA treatment [32], it is expected that TC levels decrease after CPAP treatment. Second, decreased levels of sympathetic activity [33], cortisol [34] and insulin [35] after CPAP treatment may result in decreased lipid levels. Increased levels of norepinephrine and cortisol, as well as insulin resistance, have been noted to collectively stimulate lipolysis in adipose tissue and induce syntheses of hepatic fatty acid and lipid profiles [8]. Third, it could be associated with the improvement of sleep continuity by CPAP treatment because dyslipidemia may result from sleep fragmentation [11] caused by apneic events. Finally, it could be associated with improvement of fatigue and excessive daytime sleepiness after CPAP treatment [36,37], which may result in increased levels of physical activity. However, a 10-year follow-up cohort study among elderly suggested that worsening of nocturnal oxygen desaturation was independent of changes in circulating lipids and not influenced by lipid-lowering treatments [38]. However, the changes in blood pressure remained associated with waist/hip and LDL/HDL ratios. Taken together, besides sleep apnea, other factors such as age, blood pressure and central obesity may affect lipid levels. However, our findings of meta-regression show that age, cardiometabolic diseases and obesity do not moderate the effect of CPAP on lipid levels. Future studies should be conducted to examine the underlying mechanisms for limited effects of CPAP on lipid levels in patients with OSA.

In the previous two meta-analyses with RCTs examining CPAP effects on lipid profiles, the findings of moderators for CPAP effects on lipid profiles are inconsistent. For example, one reported that a better lipid-lowering effect was observed in studies with longer follow-up duration [16], while the other reported an opposite finding [15]. In the current study, meta-regression models show that post-CPAP treatment changes in TC, as well as other lipid profiles, are not moderated by age, sex, BMI, daytime sleepiness, the severity of OSA, follow-up duration or CPAP compliance, suggesting no single moderator influences the main outcome for lipid profiles.

Our study has several clinical implications. The findings of a decrease in TC suggest that CPAP treatment improves lipid metabolism in OSA. However, such relatively small decrement of TC (−0.098 mmol/L; 3.793 mg/dL) could be the result of slightly decreased LDL and HDL after CPAP treatment. Its clinical significance should be interpreted cautiously. Future longitudinal studies should examine the clinical implications regarding decreasing cardiovascular risk at the relatively small magnitude decrease in TC. Moreover, our findings show no effects of CPAP treatment on HDL and LDL. Thus, it appears that CPAP treatment alone does not improve the lipid profiles in OSA patients with dyslipidemia, and CPAP should be combined with lifestyle modifications and anti-hyperlipidemic medications [39]. Of note, one of the RCTs addressed the effect of CPAP in patients with OSA and coronary artery disease who were already on anti-hyperlipidemic medication without any additional improvement [28,29]. Notwithstanding, the combined effect of CPAP and anti-hyperlipidemic medication might be more effective among patients with OSA free from cardiometabolic disease at baseline compared to the effects in patients who already have developed a cardiometabolic disease. In addition, barbed repositioning pharyngoplasty has been shown to improve chronic inflammation and cardiometabolic disease, which may be regarded as one efficient intervention for obese OSA patients [40,41].

The current study has some strengths to be addressed. Comparing to the previous two meta-analyses with RCTs [15,16], we included as many as twice the number of RCTs, of which seven have relatively long follow-up durations (24-to-48 weeks). Some limitations need to be acknowledged. Lipid levels are associated with diet, medications (i.e., anti-hyperlipidemic medications, insulin and beta-blockers), daily physical activity and lifestyle [42]. Unfortunately, such confounders might not be well-controlled in the current study since most of the included RCTs were not specifically designed to evaluate lipid profiles and did not provide information regarding these confounders. Furthermore, some participants using anti-hyperlipidemic medications were included, and only five studies reported the percentage of using anti-hyperlipidemic medications, which does not allow us
to eliminate its confounding effect. Future studies should fully consider the aforementioned confounding effects when examining the effects of CPAP on lipid profile. Moreover, CPAP compliance in this meta-analysis was based on the mean compliance for each study but not for each patient. Therefore, the non-significant relationship between changes in lipid profiles and CPAP compliance in meta-regression models should be interpreted cautiously and be examined in future studies. Finally, since a great part of the included participants were males (78.2%), sex-stratified designed studies are also needed.

7. Conclusions

CPAP treatment decreases TC at a small magnitude in adults with OSA. Since TC is a strong predictor for cardiometabolic diseases, our findings indicate that CPAP combined with lipid-lowering drugs are warranted for OSA patients with dyslipidemia. Future studies should be conducted to explore the potential mechanisms for CPAP treatment effects on lipid profiles.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11030596/s1, Supplementary Text. The unit conversion formulas of each lipid profile. Figure S1. Funnel plots of lipid profiles. Figure S2. Funnel plots after trim and fill for total cholesterol. Table S1. Search strategies. Table S2. List of 14 included studies. Table S3. Quality and risk of bias. Table S4 Comparison of total cholesterol before and after trim and fill. Table S5: 1. Sensitivity analyses of total cholesterol, 2. Sensitivity analyses of triglyceride, 3. Sensitivity analyses of high-density lipoprotein, 4. Sensitivity analyses of low-density lipoprotein. Table S6. Meta-regression analyses for lipid profiles.

Author Contributions: B.C. and M.G. conducted the literature search, data extraction, statistical analyses and drafted the first manuscript. Y.P., N.S., L.F.D. and G.L.-F. provided some data sources of the included studies and revised the manuscript. X.T. contributed the idea of this study and revised the manuscript. Y.L. adjudicated any inconsistency in literature search and data extraction, modified statistical analyses and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by National Natural Science Foundation of China (No. 81970087), Grant for Key Disciplinary Project of Clinical Medicine under the Guangdong High-level University Development Program, Guangdong Province Science and Technology Special Fund project (20011516870512) and 2020 Li Ka Shing Foundation Cross-Disciplinary Research Grant (2020LKSFG05B).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data that underlie the results reported in this article can be obtained by contacting the corresponding author; s_liyun@stu.edu.cn.

Conflicts of Interest: All authors report no biomedical financial interests or potential conflicts of interest.

References
1. Benjafield, A.V.; Ayas, N.T.; Eastwood, P.R.; Heinzer, R.; Ip, M.S.M.; Morrell, M.J.; Nunez, C.M.; Patel, S.R.; Penzel, T.; Pépin, J.-L.; et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis. Lancet Respir. Med. 2019, 7, 687–698. [CrossRef]
2. Peppard, P.E.; Young, T.; Barnet, J.H.; Palta, M.; Hagen, E.W.; Hla, K.M. Increased Prevalence of Sleep-Disordered Breathing in Adults. Am. J. Epidemiol. 2013, 177, 1006–1014. [CrossRef] [PubMed]
3. Gunduz, C.; Basoglu, O.K.; Hedner, J.; Zou, D.; Bonsignore, M.R.; Hein, H.; Staats, R.; Pataka, A.; Barbe, F.; Sliwinski, P.; et al. Obstructive sleep apnoea independently predicts lipid levels: Data from the European Sleep Apnea Database. Respirology 2018, 23, 1180–1189. [CrossRef] [PubMed]
4. Li, J.; Grigoryev, D.N.; Ye, S.Q.; Thorne, L.; Schwartz, A.R.; Smith, P.L.; O’Donnell, C.P.; Polotsky, V.Y. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J. Appl. Physiol. 2005, 99, 1643–1648. [CrossRef] [PubMed]
5. Trzepizur, W.; Le Vaillant, M.; Mesliier, N.; Pigeanne, T.; Masson, P.; Humeau, M.P.; Goupil, F.; Chollet, S.; Duchateau, P.H.; Gagnadoux, F. Independent association between nocturnal intermittent hypoxemia and metabolic dyslipidemia. Chest 2013, 143, 1584–1589. [CrossRef]
6. Chen, L.; Einbinder, E.; Zhang, Q.; Hasday, J.; Balke, C.W.; Scharf, S.M. Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. *Am. J. Respir. Crit. Care Med.* 2005, 172, 915–920. [CrossRef]

7. Mesarwi, O.A.; Loomba, R.; Malhotra, A. Obstructive Sleep Apnea, Hypoxia, and Nonalcoholic Fatty Liver Disease. *Am. J. Respir. Crit. Care Med.* 2019, 199, 830–841. [CrossRef]

8. Brindley, D.N.; McCann, B.; Niaura, R.; Stoney, C.M.; Suarez, E.C. Stress and lipoprotein metabolism: Modulators and mechanisms. *Metabolism* 1993, 42, 3–15. [CrossRef]

9. Borovac, J.A.; Dogas, Z.; Supe-Domic, D.; Galic, T.; Bozic, T. Catestatin serum levels are increased in male patients with obstructive sleep apnea. *Sleep Breath.* 2018, 23, 473–481. [CrossRef] [PubMed]

10. Toyama, Y.; Chin, K.; Chihara, Y.; Takegami, M.; Takahashi, K.I.; Sumi, K.; Nakamura, T.; Nakayama-Ashida, Y.; Minami, I.; Horita, S.; et al. Association between sleep apnea, sleep duration, and serum lipid profile in an urban, male, working population in Japan. *Chest* 2013, 143, 720–728. [CrossRef]

11. Chopra, S.; Rathore, A.; Younas, H.; Pham, L.V.; Gu, C.; Beselman, A.; Kim, I.-Y.; Wolfe, R.R.; Perin, J.; Polotsky, V.Y.; et al. Obstructive Sleep Apnea Dynamically Increases Nocturnal Plasma Free Fatty Acids, Glucose, and Cortisol During Sleep. *J. Clin. Endocrinol. Metab.* 2017, 102, 3172–3181. [CrossRef] [PubMed]

12. Savransky, V.; Jun, J.; Li, J.; Nanayakkara, A.; Fonti, S.; Moser, A.B.; Steele, K.E.; Sweitzer, M.E.; Patil, S.P.; Bhanot, S.; et al. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearyoyl coenzyme A desaturase. *Circ Res.* 2008, 103, 1173–1180. [CrossRef] [PubMed]

13. Drager, L.F.; Li, J.; Shin, M.-K.; Reinke, C.; Aggarwal, N.R.; Jun, J.C.; Bevans-Fonti, S.; Szatalyrd, C.; O’Byrne, S.M.; Kroupa, O.; et al. Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnea. *Eur. Hear. J.* 2011, 33, 783–790. [CrossRef] [PubMed]

14. Drager, L.F.; Yao, Q.; Hernandez, K.L.; Shin, M.-K.; Bevans-Fonti, S.; Gay, J.; Sussan, T.E.; Jun, J.C.; Myers, A.C.; Olivecrona, G.; et al. Chronic Intermittent Hypoxia Induces Atherosclerosis via Activation of Adipose Angiopoietin-like 4. *Am. J. Respir. Crit. Care Med.* 2013, 188, 240–248. [CrossRef]

15. Xu, H.; Yi, H.; Guan, J.; Yin, S. Effect of continuous positive airway pressure on lipid profile in patients with obstructive sleep apnea syndrome: A meta-analysis of randomized controlled trials. *Atherosclerosis* 2014, 234, 446–453. [CrossRef]

16. Lin, M.T.; Lin, H.H.; Lee, F.L.; Weng, I.H.; Lee, C.C.; Lai, T.C.; Liu, W.; Chen, C.-L. Beneficial effect of continuous positive airway pressure on lipid profiles in obstructive sleep apnea: A meta-analysis. *Sleep Breath* 2015, 19, 809–817. [CrossRef]

17. Sharma, S.K.; Agrawal, S.; Damodaran, D.; Sreenivas, V.; Kadhiravan, T.; Lakshmy, R.; Jagia, P.; Kumar, A. Retraction: CPAP for the metabolic syndrome in patients with obstructive sleep apnea. *N. Engl. J. Med.* 2011, 365, 2277–2286, Erratum in *N. Engl. J. Med.* 2013, 365, 1770. [CrossRef]

18. Coughlin, S.R.; Mawdsley, L.; Mugarza, J.A.; Sreenivas, V.; Kadhiravan, T.; Lakshmy, R.; Jagia, P.; Kumar, A.; et al. CPAP Treatment for Obstructive Sleep Apnea Hypopnea Syndrome on Lipid Profile: A Meta-Regression Analysis. *J. Clin. Sleep Med.* 2013, 9, 1295–1302. [CrossRef] [PubMed]

19. Comondore, V.R.; Cheema, R.; Fox, J.; Butt, A.; Mancini, G.B.J.; Fleetham, J.A.; Ryan, C.F.; Chan, S.; Ayas, N.T. The Impact of CPAP on Cardiovascular Biomarkers in Minimally Symptomatic Patients with Obstructive Sleep Apnea: A Pilot Feasibility Randomized Crossover Trial. *Lung* 2008, 187, 17–22. [CrossRef]

20. Phillips, C.L.; Yee, B.J.; Marshall, N.S.; Liu, P.Y.; Sullivan, D.R.; Grunstein, R.R. Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea. A randomized, placebo-controlled crossover trial. *Am. J. Respir. Crit. Care Med.* 2011, 184, 355–361. [CrossRef]

21. Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Available online: https://training.cochrane.org/handbook/archive/v5.1/ (accessed on 1 September 2021).

22. Nadeem, R.; Singh, M.; Nida, M.; Kwon, S.; Sajid, H.; Witkowski, J.; Pahomov, E.; Shah, K.; Park, W.; Champeau, D. Effect of continuous positive airway pressure on lipid profiles in patients with obstructive sleep apnea. *Crit. Care Med.* 2013, 41, 1295–1302. [CrossRef] [PubMed]

23. Nadeem, R.; Singh, M.; Nida, M.; Kwon, S.; Sajid, H.; Witkowski, J.; Pahomov, E.; Shah, K.; Park, W.; Champeau, D. Obstructive sleep apnea and cardiovascular outcomes in men with obstructive sleep apnea: A randomized, placebo-controlled crossover trial. *J. Am. Coll. Cardiol.* 2018, 72, 1141–1156. [CrossRef] [PubMed]

24. Ference, B.A.; Graham, I.; Tokgozoglu, L.; Catapano, A.L. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. *J. Am. Coll. Cardiol.* 2017, 72, 1141–1156. [CrossRef] [PubMed]

25. Marín, J.M.; Carrizo, S.J.; Vicente, E.; Agustí, A.G. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: An observational study. *Lancet* 2005, 365, 1046–1053. [CrossRef]

26. Drager, L.F.; Togeiro, S.M.; Polotsky, V.Y.; Lorenzi-Filho, G. Obstructive sleep apnea: A cardiometabolic risk in obesity and the metabolic syndrome. *J. Am. Coll. Cardiol.* 2013, 62, 569–576. [CrossRef] [PubMed]

27. Shamseer, L.; Moher, D.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. *BMJ* 2015, 350, g7647. [CrossRef]

28. Peker, Y.; Glantz, H.; Eulenburg, C.; Wegscheider, K.; Herlitz, J.; Thunstrom, E. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial. *Am. J. Respir. Crit. Care Med.* 2016, 194, 613–620. [CrossRef]
29. Celik, Y.; Balcan, B.; Peker, Y. CPAP Intervention as an Add-On Treatment to Lipid-Lowering Medication in Coronary Artery Disease Patients with Obstructive Sleep Apnea in the RICCADSA Trial. *J. Clin. Med.* 2022, 11, 273. [CrossRef]

30. Higgins, J.P.; Altman, D.G.; Gøtzsche, P.C.; Jüni, P.; Moher, D.; Oxman, A.D.; Savovic, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A.C. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* 2011, 343, d5928. [CrossRef]

31. Thornton, A.; Lee, P. Publication bias in meta-analysis: Its causes and consequences. *J. Clin. Epidemiol.* 2000, 53, 207–216. [CrossRef]

32. Robinson, G.V.; Pepperell, J.C.T.; Segal, H.C.; Davies, R.J.O.; Stradling, J.R. Circulating cardiovascular risk factors in obstructive sleep apnoea: Data from randomised controlled trials. *Thorax* 2004, 59, 777–782. [CrossRef] [PubMed]

33. Chen, B.; Somers, V.K.; Tang, X.; Li, Y. Moderating Effect of BMI on the Relationship Between Sympathetic Activation and Blood Pressure in Males with Obstructive Sleep Apnea. *Nat. Sci. Sleep* 2021, 13, 339–348. [CrossRef] [PubMed]

34. Schmoller, A.; Eberhardt, F.; Jauch-Chara, K.; Schweiger, U.; Zabel, P.; Peters, A.; Schultes, B.; Oltmanns, K.M. Continuous positive airway pressure therapy decreases evening cortisol concentrations in patients with severe obstructive sleep apnea. *Metabolism* 2009, 58, 848–853. [CrossRef] [PubMed]

35. Shang, W.; Zhang, Y.; Wang, G.; Han, D. Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta-analysis. *Diabetes Obes. Metab.* 2021, 23, 540–548. [CrossRef]

36. Vasquez, M.M.; Goodwin, J.L.; Drescher, A.A.; Smith, T.W.; Quan, S.F. Associations of dietary intake and physical activity with sleep disordered breathing in the Apnea Positive Pressure Long-Term Efficacy Study (APPLES). *J. Clin. Sleep Med.* 2008, 4, 411–418. [CrossRef]

37. Katcher, H.I.; Hill, A.M.; Lanford, J.L.; Yoo, J.S.; Kris-Etherton, P.M. Lifestyle Approaches and Dietary Strategies to Lower LDL-Cholesterol and Triglycerides and Raise HDL-Cholesterol. *Endocrinol. Metab. Clin. N. Am.* 2009, 38, 45–78. [CrossRef]

38. Monneret, D.; Barthélémy, J.C.; Hupin, D.; Maudoux, D.; Celle, S.; Sforza, E.; Roche, F. Serum lipid profile, sleep–disordered breathing and blood pressure in the elderly: A 10-year follow-up of the PROOF-SYNAPSE cohort. *Sleep Med.* 2017, 39, 14–22. [CrossRef]

39. Chirinos, J.A.; Gurubhagavatula, I.; Teff, K.; Rader, D.J.; Wadden, T.A.; Townsend, R.; Foster, G.D.; Maislin, G.; Saif, H.; Broderick, P.; et al. CPAP, weight loss, or both for obstructive sleep apnea. *N. Engl. J. Med.* 2014, 370, 2265–2275. [CrossRef]

40. Binar, M.; Akcam, T.; Karakoc, O.; Sagkan, R.I.; Musabak, U.; Gerek, M. A new surgical technique versus an old marker: Can expansion sphincter pharyngoplasty reduce C-reactive protein levels in patients with obstructive sleep apnea? *Eur. Arch. Otorhinolaryngol.* 2017, 274, 829–836. [CrossRef]

41. Iannella, G.; Lechien, J.R.; Perrone, T.; Meccariello, G.; Cammaroto, G.; Cannavici, A.; Burgio, L.; Maniaci, A.; Cocuzza, S.; Di Luca, M.; et al. Barbed reposition pharyngoplasty (BRP) in obstructive sleep apnea treatment: State of the art. *Am. J. Otolaryngol.* 2022, 43, 103197. [CrossRef]

42. Barros, D.; Garcia-Rio, F. Obstructive sleep apnea and dyslipidemia: From animal models to clinical evidence. *Sleep* 2019, 42, zs236. [CrossRef] [PubMed]